sb 202190 has been researched along with Carcinoma, Renal Cell in 1 studies
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase
Carcinoma, Renal Cell: A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ch'ng, WC | 1 |
| Abd-Aziz, N | 1 |
| Ong, MH | 1 |
| Stanbridge, EJ | 1 |
| Shafee, N | 1 |
1 other study available for sb 202190 and Carcinoma, Renal Cell
| Article | Year |
|---|---|
Human renal carcinoma cells respond to Newcastle disease virus infection through activation of the p38 MAPK/NF-κB/IκBα pathway.
Topics: Active Transport, Cell Nucleus; Apoptosis; Blotting, Western; Carcinoma, Renal Cell; Cell Line, Tumo | 2015 |